摘要
目的观察放疗联合紫杉醇与卡铂同步化疗治疗中晚期宫颈癌的临床疗效及毒副反应。方法我科于2007年6月至2010年6月收治了43例中晚期宫颈鳞癌患者。22例患者行单纯放疗(RT组):体外照射+后装;21例患者行放化综合治疗(RCT组):放疗方法同单放组,同期紫杉醇联合卡铂方案(TC)化疗2个周期。采用Kaplan-Meier法行生存分析,两组计数资料比较采用χ2检验。结果 RCT组总有效率为95.2%,完全缓解(CR)率为80.9%;RT组总有效率为72.7%,CR率为45.5%;总有效率及CR率差异均有统计学意义(P<0.05)。1年生存率:RCT组为95.2%,RT组为90.9%,差异无统计学意义(P>0.05);3年生存率:RCT组为81.2%,RT组为56.8%,差异有统计学意义(P<0.05)。RCT组骨髓抑制和胃肠道反应发生率高于RT组,差异有统计学意义(P<0.01),但多为轻度反应,且RCT组仅有1例Ⅲ度骨髓抑制。放射性直肠炎及膀胱炎两组差异无统计学意义(P>0.05)。毒副反应经积极处理后不影响治疗。结论放疗联合紫杉醇与卡铂同步放化疗可提高中晚期宫颈癌的临床疗效,患者耐受性好。
Objective To investigate the efficacy and the adverse effects in patients with cervical cancer who were treated with radiotherapy and concurrent chemotherapy by paclitaxel and carboplatin.Methods Forty-three patients with stage Ⅱb～Ⅳa cervical squamous cell carcinoma were enrolled in this study.Twenty-two of the patients were treated with radiotherapy alone （RT group,radiotherapy and intracavitary brachytherapy）,and twenty-one were treated with radiotherapy and concurrent chemotherapy by paclitaxel and carboplatin （RCT group,chemotherapy for two circles）.Results The overall response rate,complete response （CR） rate were 95.2%,80.9% for RCT group,and 72.7%,45.5% for the RT group,with statistically significant difference between the two groups （P〈0.05）.The l-year survival rate for two groups were 95.2 % and 90.9%,respectively,with no statistically significant difference （P〉0.05）.The 3-year survival rate was 81.2% and 56.8%,respectively,with statistically significant difference （P〈0.05）.The main side effects were also compared in two groups：the incidence of myelosuppression and gastrointestinal reaction were significantly higher in the RCT group （P〈0.01）,and most of them were mild （Ⅰ ～ Ⅱ grade）.Only one case of Ⅲ grade myelosuppression was found in the RCT group.The two groups showed no statistically significant difference between the two groups in radiation proctitis and cystitis （P〉0.2）.The side effects were well tolerated in two groups.Conclusion Radiotherapy and concurrent chemotherapy by paclitaxel and carboplatin can be considered as an effective and feasible approach to treat cervical cancer.It can significantly improve the clinical efficacy and the adverse reactions are slight.
出处
《海南医学》
CAS
2013年第22期3320-3322,共3页
Hainan Medical Journal
关键词
中晚期宫颈癌
放疗
紫杉醇
卡铂
同步化疗
Advanced cervical cancer
Radiotherapy
Paclitaxel
Carboplatin
concurrent chemotherapy
